Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
|Articles|October 25, 2021
Pharmacy Clinical Pearl of the Day: Bulimia Nervosa
Author(s)Saro Arakelians, PharmD
Patients with bulimia may use different methods to get rid of calories and prevent weight gain, such as self-inducing vomiting on a regular basis.
Advertisement
Clinical Pearl of the Day: Bulimia Nervosa
Bulimia nervosa, commonly called bulimia, is a serious, potentially life-threatening eating disorder.
Insight:
- People with bulimia may secretly binge and eat large amounts of food and then purge.
- Patients may use different methods to get rid of the calories and prevent weight gain, such as self-inducing vomiting on a regular basis, misuse of laxatives, weight loss supplements, diuretics or enemas, strict dieting, or excessive exercise routines.
- Symptoms include being overly pre-occupied with body shape and weight; living in fear of gaining weight; eating large amounts of food and forcing vomiting; using laxatives, diuretics, or enemas; fasting; restricting calories; and using dietary supplements or herbal products to lose weight.
- Risk factors include people focused on dieting, patients with family history, or people with psychological and mental disorders, such as anxiety and depression.
- Treatment options would include coping and support, learning about bulimia, getting the right nutrition, being cautious with exercise, dietary supplements and herbs.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
3
Inside the New Consensus Recommendations for Acute Stroke Care
4
The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind
5